Koninklijke Philips NV vs Tesla, Inc. — how do they compare? Koninklijke Philips NV trades at $24.38 (market cap $23.68B), while Tesla, Inc. trades at $379.44 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 62.9× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays a 4.21% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Tesla, Inc. for 88 Days on average.
| PHG | TSLA | |
|---|---|---|
Market Cap | $23.68B | $1.49T |
Volume | 1,443,075 | 25,496,215 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.91 | $489.88 |
52-Week Low | $23.81 | $298.16 |
Typical Hold Time | 84 Days | 88 Days |
Enterprise Value | $30.07B | $1.46T |
Dividend Yield | 4.21% | — |
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
Tesla (TSLA) trades at $377.61, down 0.81% amid mixed signals. Technical analysis shows a bullish trend with key support at $375, while fundamentals reveal high valuation multiples (P/E 349.82) despite recent earnings beats. The company faces margin compression with net income declining to $3.79B in 2025. Recent news highlights regulatory approval for driver-assistance software in Europe (Reuters, 2026-04-10) and a potential cheaper EV model launch.
Tesla's investment case balances innovation leadership against valuation concerns. Upside potential exists from autonomous driving advances and energy/robotics growth, but risks include intense EV competition and execution challenges. Analysts maintain a cautious stance with 41% buy ratings and a $441.36 consensus target, suggesting modest upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →